Identification of PTGR2 inhibitors as a new therapeutic strategy for diabetes and obesity

Identification of PTGR2 inhibitors as a new therapeutic strategy for diabetes and obesity

Abstract Peroxisome proliferator-activated receptor γ (PPARγ) is a master transcriptional regulator of systemic insulin sensitivity and energy balance. The anti-diabetic drug thiazolidinediones (TZDs) are potent synthetic PPARγ ligands with undesirable side effects, including obesity, fluid retentio...

Full description

Saved in:
Bibliographic Details
Main Authors: Yi-Cheng Chang, Meng-Lun Hsieh, Hsiao-Lin Lee, Siow-Wey Hee, Chi-Fon Chang, Hsin-Yung Yen, Yi-An Chen, Yet-Ran Chen, Ya-Wen Chou, Fu-An Li, Yi-Yu Ke, Shih-Yi Chen, Ming-Shiu Hung, Alfur Fu-Hsin Hung, Jing-Yong Huang, Chu-Hsuan Chiu, Shih-Yao Lin, Sheue-Fang Shih, Chih-Neng Hsu, Juey-Jen Hwang, Teng-Kuang Yeh, Ting-Jen Rachel Cheng, Karen Chia-Wen Liao, Daniel Laio, Shu-Wha Lin, Tzu-Yu Chen, Chun-Mei Hu, Ulla Vogel, Daniel Saar, Birthe B Kragelund, Lun Kelvin Tsou, Yu-Hua Tseng, Lee-Ming Chuang
Format: Article
Language:English
Published: Springer Nature 2025-03-01
Series:EMBO Molecular Medicine
Subjects:
PTGR2
Diabetes
Obesity
PPARγ
15-keto-PGE2
Online Access:https://doi.org/10.1038/s44321-025-00216-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s44321-025-00216-4

Similar Items